Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.20
+0.14 (2.67%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Amylyx Pharmaceuticals stock have an average target of 8.50, with a low estimate of 4.00 and a high estimate of 12. The average target predicts an increase of 63.62% from the current stock price of 5.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 4 | 4 | 4 | 4 | 4 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Hold → Buy Upgrades $3 → $7 | Hold → Buy | Upgrades | $3 → $7 | +34.74% | Apr 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +130.99% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +130.99% | Dec 5, 2024 |
| Baird | Baird | Hold → Buy Upgrades $3 → $11 | Hold → Buy | Upgrades | $3 → $11 | +111.74% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $12 | Strong Buy | Maintains | $8 → $12 | +130.99% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
n/a
from 87.37M
Revenue Next Year
164.48K
EPS This Year
-1.92
from -4.43
EPS Next Year
-1.55
from -1.92
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 677,250 | 26.3M | ||
| Avg | n/a | 164,475 | 12.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 15,859.9% | ||
| Avg | - | - | 7,686.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.67 | -1.00 | -1.14 | ||
| Avg | -1.92 | -1.55 | -1.70 | ||
| Low | -2.21 | -2.12 | -2.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.